Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis

다국어 초록 (Multilingual Abstract)

Purpose: Prominin1/CD133 has become the ideal marker for cancer stem cells (CSCs) detection in human tumors. In this study we examined the expression of this marker in several breast cancer specimens to associate CSCs percentage with risk factor for this neoplasia. Methods: We examined specimens from 12 patients using CD133 and CD44 antibodies for CSCs immunohistochemistry detection and for flow cytometry analysis. For each patient, we also performed the immunohistochemical staining to evaluate the expression of estrogen receptor, progesterone receptor, c-erbB-2, Ki67, and E-cadherin markers. A Taqman probe for CD133 was used for mRNA quantification by realtime polymerase chain reaction. Results: Prominin-1 expression was heterogeneous in different carcinomas but was strikingly hyperexpressed in a tubulolobular variant of breast cancer. The results were confirmed by all three methods. Conclusion: Our data, although produced on a limited number of samples, showed an particularly high expression of stem cell marker CD133 in a breast cancer variant, generally with a good prognosis. Since CSCs detection by CD133 has been described as an important prognostic factor for several human cancers, we suggest the importance of detecting stem cell compartiments in all histotypes of breast carcinomas.

참고문헌 (Reference)

• 1 Chumas J., "Tubulolobular carcinoma of the breast" 22 : 903-904, 1998
• 2 Rappa G, "The stem cell-associated antigen CD133(Prominin-1) is a molecular therapeutic target for metastatic melanoma" 26 : 3008-3017, 2008
• 3 Honeth G, "The CD44+/CD24- phenotype is enriched in basallike breast tumors" 10 : R53-, 2008
• 4 Takebe N, "Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways" 8 : 97-106, 2011
• 5 Ferrandina G, "Targeting CD133 antigen in cancer" 13 : 823-837, 2009
• 6 Al-Hajj M, "Self-renewal and solid tumor stem cells" 23 : 7274-7282, 2004
• 7 Creighton CJ, "Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features" 106 : 13820-13825, 2009
• 8 Lorico A, "Phenotypic heterogeneity of breast cancer stem cells" 2011 : 135039-, 2011
• 9 Rappa G, "Phenotypic characterization of mammosphereforming cells from the human MA-11 breast carcinoma cell line" 316 : 1576-1586, 2010
• 10 Mimeault M, "New promising drug targets in cancer- and metastasis- initiating cells" 15 : 354-364, 2010
• 11 Kim HJ, "Isolation of CD24(high) and CD24(low/-) cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7" 258 : 98-108, 2007
• 12 Liu Q, "Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas" 122 : 2763-2769, 2009
• 13 Zhao P, "Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma" 102 : 1107-1111, 2011
• 14 Maitland NJ, "Cancer stem cells: a therapeutic target?" 12 : 662-673, 2010
• 15 Ailles LE, "Cancer stem cells in solid tumors" 18 : 460-466, 2007
• 16 Jordan CT, "Cancer stem cells" 355 : 1253-1261, 2006
• 17 Sheridan C, "CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis" 8 : R59-, 2006
• 18 Wu Y, "CD133 as a marker for cancer stem cells: progresses and concerns" 18 : 1127-1134, 2009
• 19 Al-Mulla F, "BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry" 53 : 621-629, 2005
• 20 Smith LM, "Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibodydrug conjugates in hepatocellular and gastric cancers" 99 : 100-109, 2008
• 21 Fargeas CA, "AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rationalnomenclature" 21 : 506-508, 2003
• 22 Miraglia S, "A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning" 90 : 5013-5021, 1997